Vixtimotamab (AMV-564; TandAb T564) 是一种双特异性四价串联抗体 (TandAb)，靶向人CD33和CD3抗原。Vixtimotamab 可用于急性髓系白血病 (AML) 的研究。
| 生物活性 | Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets humanCD33and humanCD3antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML)[1]. |
| IC50& Target | KD: 0.3 nM (CD33, HL-60 cells), 5.1 nM (CD3, Human T cells)[1] |
体外研究
(In Vitro) | Vixtimotamab (TandAb T564; 24 h) 诱导 CD25 和 CD69, EC50分别为 1 pM 和 2 pM[1]。
Vixtimotamab (TandAb T564; 4 days) 诱导 PBMCs 中的 T 细胞增殖，EC50为 3 pM[1]。
Vixtimotamab (TandAb T564; 25 pM, 48 h) 显示对 HL-60 和 KG-1a 细胞的细胞毒性[1]。
Cell Cytotoxicity Assay[1] | Cell Line: | HL-60 and KG-1a cells | | Concentration: | 25 pM | | Incubation Time: | 48 h | | Result: | Showed cytotoxicity of 86.0±1.4% and 81.3±1.5% against HL-60 and KG-1a cells, respectively. |
|
体内研究
(In Vivo) | Vixtimotamab (TandAb T564; 0.1-10 μg/mouse, i.v.; 5 days) 在预防性 HL-60 移植 NOD/scid 小鼠模型中显示剂量依赖性肿瘤生长延迟[1]。
Vixtimotamab (TandAb T564; 50 μg/mouse/d, i.v.; 7 days) 在建立的 HL-60 移植 NOD/scid 小鼠模型中显著抑制肿瘤生长[1]。
| Animal Model: | 8-week-old NOD/scid female mice, weighing 20.7 ± 1.48 g, prophylactic HL-60 graft model[1] | | Dosage: | 0.1, 1, or 10 μg/mouse | | Administration: | Intravenous injection, on days 0, 1, 2, 3, and 4 | | Result: | Demonstrated dose-dependent tumor growth delay. |
|
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com